These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31529097)

  • 1. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.
    Devin JK; Nian H; Celedonio JE; Wright P; Brown NJ
    J Clin Endocrinol Metab; 2020 Jan; 105(1):136-51. PubMed ID: 31529097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.
    Wilson JR; Brown NJ; Nian H; Yu C; Bidlingmaier M; Devin JK
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
    Ferjan S; Janez A; Jensterle M
    Endocr Pract; 2018 Jan; 24(1):69-77. PubMed ID: 29144805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dipeptidyl peptidase-4 inhibitors on transforming growth factor-β1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats.
    Wang F; Zhang ZF; He YR; Wu HY; Wei SS
    J Obstet Gynaecol Res; 2019 Mar; 45(3):600-608. PubMed ID: 30515927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial.
    Nahon KJ; Doornink F; Straat ME; Botani K; Martinez-Tellez B; Abreu-Vieira G; van Klinken JB; Voortman GJ; Friesema ECH; Ruiz JR; van Velden FHP; de Geus-Oei LF; Smit F; Pereira Arias-Bouda LM; Berbée JFP; Jazet IM; Boon MR; Rensen PCN
    Diabetologia; 2018 Nov; 61(11):2386-2397. PubMed ID: 30145664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.
    Kelly A; Sheikh S; Stefanovski D; Peleckis AJ; Nyirjesy SC; Eiel JN; Sidhaye A; Localio R; Gallop R; De Leon DD; Hadjiliadis D; Rubenstein RC; Rickels MR
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2617-2634. PubMed ID: 34406395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
    Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute pharmacodynamic responses to sitagliptin: Drug-induced increase in early insulin secretion in oral glucose tolerance test.
    Beitelshees AL; Streeten EA; Shahidzadeh Yazdi Z; Whitlatch HB; Mitchell BD; Shuldiner AR; Montasser ME; Taylor SI
    Clin Transl Sci; 2024 May; 17(5):e13809. PubMed ID: 38700326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
    Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
    Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.
    Kaku K; Kadowaki T; Terauchi Y; Okamoto T; Sato A; Okuyama K; Arjona Ferreira JC; Goldstein BJ
    Diabetes Obes Metab; 2015 Nov; 17(11):1033-41. PubMed ID: 26094974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
    Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
    Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
    Kurozumi A; Okada Y; Sugai K; Torimoto K; Tanaka Y
    J UOEH; 2018; 40(1):1-9. PubMed ID: 29553070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study.
    Ferjan S; Janez A; Jensterle M
    Metab Syndr Relat Disord; 2017 Dec; 15(10):515-520. PubMed ID: 29064743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes.
    Scalzo RL; Rafferty D; Schauer I; Huebschmann AG; Cree-Green M; Reusch JEB; Regensteiner JG
    J Diabetes Complications; 2019 Aug; 33(8):561-566. PubMed ID: 31182338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
    Bock G; Dalla Man C; Micheletto F; Basu R; Giesler PD; Laugen J; Deacon CF; Holst JJ; Toffolo G; Cobelli C; Rizza RA; Vella A
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):189-96. PubMed ID: 20039889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.